JOSÉ LUIS
GONZÁLEZ LARRIBA
Catedrático de universidad
Universidad Autónoma de Madrid
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Universidad Autónoma de Madrid (16)
2024
-
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP
Clinical and Translational Oncology
2016
2010
-
Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer
Journal of Translational Medicine, Vol. 8
2009
-
Assessing the value of preoperative chemotherapy in early-stage non-small cell lung cancer: mature data and prognostic factors analysis of a Phase III randomized trial of surgery alone vs preoperative Paclitaxel/Carboplatin (PC) vs postoperative PC. Final NATCH data. A Spanish Lung Cancer Group Trial
EJC SUPPLEMENTS
-
Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-α as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population
Annals of Oncology, Vol. 20, Núm. 11, pp. 1803-1812
-
Screening for epidermal growth factor receptor mutations in lung cancer
New England Journal of Medicine, Vol. 361, Núm. 10, pp. 958-967
2007
-
Elevated levels of thioredoxin (Trx) in serum correlate with poor outcome in docetaxel (doc)/cisplatin (cis)-treated stage IV non-small-cell lung cancer (NSCLC) patients (pts)
EJC SUPPLEMENTS
-
Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non-small-cell lung cancer patients: The Spanish Lung Cancer Group trial 9901
Journal of Clinical Oncology, Vol. 25, Núm. 30, pp. 4736-4742
-
XPD 312 single nucleotide polymorphism (SNP) predicts survival in stage IIIA-B non-sinall-cell lung cancer (NSCLC) patients (pts) < 59 years (y) treated with chemotherapy followed by surgery
EJC SUPPLEMENTS
2005
-
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients
Annals of Oncology, Vol. 16, Núm. 7, pp. 1081-1086
2004
-
Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer
Clinical Lung Cancer, Vol. 5, Núm. 6, pp. 360-365
2002
1999
-
Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations
Journal of Clinical Oncology, Vol. 17, Núm. 6, pp. 1786-1793
1990
1984
-
TRATAMIENTO DEL CARCINOMA BRONCOPULMONAR MICROCELULAR CON LA ASOCIACION DE CICLOFOSFAMIDA Y VP-16
Medicina Clinica, Vol. 82, Núm. 19, pp. 836-839
1983
-
Action of alkaloids from podophyllin on the response of pancreatic beta-cells of the rabbit to tolbutamide
Revista española de oncología, Vol. 30, Núm. 4, pp. 485-490